trending Market Intelligence /marketintelligence/en/news-insights/trending/ypxtfyciktfutryrmbamaw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Pulmatrix to raise $15.2M through public offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Pulmatrix to raise $15.2M through public offering

Pulmatrix Inc. priced an offering of 23,500,000 units to raise $15.2 million.

Each unit is made up of a common stock and two separate series of share purchase warrants. Series A warrants are exchangeable for a common stock of the company at 65 cents each, while series B warrants can be exchanged for 75 cents each.

Oppenheimer & Co. Inc. is acting as the sole book-running manager for the offering, which is expected to close by April 3. The offering's underwriters have an option to buy an additional 1,150,000 stocks.

The Lexington, Mass.-based pharmaceutical company intends to use the net proceeds of this offering to develop its asthma drug Pulmazole.